515 related articles for article (PubMed ID: 29764589)
21. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
23. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
25. Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
Taus Á; Camacho L; Rocha P; Hardy-Werbin M; Pijuan L; Piquer G; López E; Dalmases A; Longarón R; Clavé S; Salido M; Albanell J; Bellosillo B; Arriola E
Clin Lung Cancer; 2018 Sep; 19(5):387-394.e2. PubMed ID: 29656868
[TBL] [Abstract][Full Text] [Related]
26. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
27. Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.
Cui S; Ye L; Wang H; Chu T; Zhao Y; Gu A; Xiong L; Shi C; Jiang L
Clin Lung Cancer; 2018 May; 19(3):e313-e322. PubMed ID: 29329944
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
[TBL] [Abstract][Full Text] [Related]
29. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
[TBL] [Abstract][Full Text] [Related]
32. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.
Isobe K; Hata Y; Tochigi N; Kaburaki K; Kobayashi H; Makino T; Otsuka H; Ishida F; Hirota N; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Iyoda A; Homma S
Cancer Genomics Proteomics; 2015; 12(1):31-7. PubMed ID: 25560642
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
35. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
36. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
[TBL] [Abstract][Full Text] [Related]
37. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
[TBL] [Abstract][Full Text] [Related]
38. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Lee YJ; Yoon KA; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
Clin Cancer Res; 2011 Aug; 17(15):5179-87. PubMed ID: 21653691
[TBL] [Abstract][Full Text] [Related]
39. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
40. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
